Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks
Leukemia Research,

Huang H et al. – The results suggest that acute promyelocytic leukemia (APL) patients benefit from combination all–trans retinoic acid (ATRA)/arsenic trioxide (ATO)/chemotherapy, and that this regimen is especially beneficial for patients with high–risk prognostic factors.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Internal Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Internal Medicine Articles

Indexed Journals in Internal Medicine: New England Journal of Medicine, The Lancet, Archives of Internal Medicinemore